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Abstract
Background:  The Fischer 344/NHsd rat undergoes age-related, progressive, high-frequency
hearing loss beginning at age 12 months. The loss has been linked to defects/death in the outer hair
cells related to oxidative stress originating in the mitochondria. Acetyl L-carnitine (ALCAR) is
known to enhance mitochondrial bioenergetics and membrane efficiency. Therefore, ALCAR was
targeted as a possible pharmacologic intervention to prevent, or even restore, hearing loss from
aging.
Methods: Three different paradigms were used to deliver ALCAR to aging Fischer 344/NHsd rats.
Rats in each condition had their hearing evaluated by auditory brainstem responses before, during,
and after treatment. First, 24-month-old rats were given ALCAR (100 mg/kg dissolved 25 mg/ml in
saline) by IP injection daily for one month. Second, 18-month-old rats were given ALCAR (100 mg/
kg) by oral gavage for 90 days. Third, 15-month-old rats were given ALCAR (100 mg/kg) by oral
gavage for 90 days. Control rats in each condition received saline by i.p. injection or gavage.
Results: Hearing thresholds of the three sets of ALCAR-treated animals were never significantly
different from their matched controls before, during, or after the treatments at any of the five test
stimuli (5, 10, 20, and 40 kHz tone bursts and a click).
Conclusion: The current study does not provide evidence that age-related hearing loss in the
Fischer 344/NHsd rat can be altered with systemic administration of ALCAR.
Background
The Fischer 344/NHsd (F344/NHsd) is an inbred, albino
rat strain with a median life span of 28–31 months [1]. Its
limited inter-animal variability makes it a useful candi-
date for the study of age-related hearing loss (ARHL). The
F344/NHsd rat develops a progressive hearing loss that
begins in the high frequencies and includes lower fre-
quencies as the animal ages. The underlying pathology
has been linked in part to a progressive loss of the outer
hair cells (OHC), but the main contributor to the ARHL
appears to be dysfunction of surviving OHC [2]. That
OHC deterioration has been linked to oxidative stress.
Age-related oxidative stress in the cochlea has been
observed in a number of ARHL models [3-5]. Aging of the
F344/NHsd rat has been linked to an accumulation of
mitochondrial genetic deletions, suggesting the possibil-
ity that the mitochondria are a significant source of reac-
tive oxygen species in the aging F344 rat cochlea [6,7]. The
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implication for ARHL was that increased reactive oxygen
species in the OHC lead loss of OHC transduction due to
metabolic insufficiency, with the long-term consequence
of OHC death.
Because ARHL is such a pervasive, growing health prob-
lem [8,9], one of the ongoing research goals on ARHL is
the development of intervention strategies to prevent, or
potentially reverse, the progressive hearing loss. Caloric
restriction and treatment with various antioxidants and
pro-antioxidant molecules have delivered mixed results in
various animal models [10-12]. Acetyl L-carnitine
(ALCAR) is a molecule that enhances mitochondria mem-
brane efficiency and bioenergetics, as well as having anti-
oxidant properties. Seidman (2000) showed that
treatment with ALCAR (300 mg/kg daily treatments) actu-
ally improved a group of F344 rats' hearing thresholds as
they aged from 24 months to 26 months [10]. The impli-
cation was that improvement in mitochondrial efficiency
not only led to reduced oxidative stress in the cochlea, but
perhaps restored function to OHC that were alive but dys-
functional.
The working hypothesis for the current study was that
long-term ALCAR treatment could prevent the loss of
mitochondrial efficiency, which would lead to prevention
of the loss of OHC function, leading to a reduction in the
progression of ARHL in middle-aged (15–18 months)
F344/NHsd rats, and/or restoration of some of the lost
hearing in the middle-aged rats and rats of advanced age
(24 months) that were already showing substantial hear-
ing loss.
Methods
A total of 44 F344/NHsd inbred male albino rats were
used in the studies. They were obtained from Harlan Lab-
oratories at 15 months-old (n = 18), 18 months-old (n =
18), and 24 months-old (n = 8). The minimum 15-
month-old rats were chosen because they had already
developed significant hearing loss 9 (10–20 dB in the 5–
20 kHz range, 30–40 at 40 kHz [2]). The goal of the study
was to restrict development of further hearing loss, and to
possibly reverse some of the hearing loss already devel-
oped. Between 15 and 18 months, a loss of 10–20 dB
across frequencies was anticipated. Between 18 and 23
months, a 15–30 dB loss was expected across frequencies.
The animals were housed in a quiet colony (<45 dBA). All
procedures involving use and care of the animals were
reviewed and approved by the State University of New
York at Buffalo Institutional Animal Care and Use Com-
mittee.
Auditory Brainstem Response (ABR) testing
In order to assess the rate of hearing loss with age as well
as the shape of the audiogram, the rats were tested for
hearing sensitivity using free-field ABR thresholds. The
animals were anesthetized with inhalant isoflurane (4%
for induction, 1.5% for maintenance, 1 L/min O2 flow
rate). Needle recording electrodes were placed at the ver-
tex (non-inverting), below the left pinna (inverting) and
behind the shoulder blade (ground). During ABR record-
ing, the rats were placed on a homeothermic blanket to
maintain body temperature. Test stimuli consisted of
alternating phase tone bursts at frequencies of 5, 10, 20,
and 40 kHz, as well as a click. Signals were generated using
Tucker Davis Technologies (TDT, Gainesville, FL) SigGen
software. Each tone burst (1 msec duration) was gated
through a Blackmann window, and had a 0.5 msec rise/
fall time with no plateau. The click had a 25 μsec duration,
and was presented with alternating polarity. Stimuli were
presented at a rate of 21/sec. Signals were routed to a Leaf
tweeter (model AS-TH400A) positioned at zero degrees
azimuth, 17 cm from the vertex of each rat's head. Acous-
tic stimuli were calibrated prior to each testing session, by
recording the output of the speaker with a microphone
placed at the animals' head level. The rats' evoked
responses were collected in a 12.5 msec time window, and
amplified with a gain of 50,000, using a TDT Headstage-4
bioamplifier, and bandpass filtered from 100–3000 Hz.
250 sweeps were averaged at each stimulus level using
TDT BioSig software. The level of the signal was decreased
in 5 dB steps from 90 dB pSPL to a level 15 dB below that
of the lowest level that evoked a detectable and repeatable
response. Threshold was recorded as the lowest level at
which a detectable response was elicited and could be
repeated.
ALCAR treatments
In order to attempt to slow the progression of ARHL in the
F344/NHsd rats, two experiments were run. In the first
experiment, 15 month-old (n = 9 treated, 9 controls) were
treated with ALCAR (100 mg/kg dissolved 25 mg/ml in
sterile saline) by oral gavage once daily for 90 days. The
control animals received saline by oral gavage. In the sec-
ond experiment, 18 month-old rats (n = 9 treated, 9 con-
trols) were treated for 90 days with ALCAR by oral gavage,
with controls receiving saline.
In order to attempt to reverse some the already-estab-
lished hearing loss in F344/NHsd rats of advanced age,
eight 24 month-old rats (4 treated, 4 controls) were given
ALCAR (100 mg/kg dissolved 25 mg/ml in sterile saline,
pH adjusted to 7.2) by intraperitoneal (i.p.) injection
once daily for 30 days. Control animals received i.p. injec-
tions of saline. The 100 mg/kg dose of ALCAR was chosen
based on previous use of ALCAR to protect against noise-
induced hearing loss in our laboratory and in a previous
publication [12].Journal of Negative Results in BioMedicine 2008, 7:4 http://www.jnrbm.com/content/7/1/4
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Weights and hearing status of all animals in the studies
were compared to untreated, unhandled historical con-
trols to assure that the gavaging process and the possible
stress of daily handling did not alter the animals' aging
process.
Statistical Analysis
Three-factor ANOVAs (Treatment group × Time of test ×
Stimulus frequency) was used to analyze differences
between the mean ABR thresholds of the different groups
across the five different test stimuli (click, 5, 10, 20, and
40 kHz tone bursts). Treatment group and Frequency were
analyzed as between-subjects variables. If a significant
main effect occurred for Time of test or Frequency, post
hoc testing with Tukey A tests was performed to delineate
the nature of the differences. The three separate studies
were analyzed separately from one another.
Results
The first experiment was conducted with rats starting at 15
months of age (n = 9 treated, 9 controls). ABR thresholds
were measured at 15 months (pre-treatment), 16, 17, and
18 months (final test after treatment concluded). Figure 1
displays the thresholds at the 15-month test and the 18-
month test. Thresholds were compared between the
treated and control groups at all four time points and
across each test stimulus. Three-factor ANOVA revealed
no significant interactions involving treatment group. A
significant interaction of Time of test × Frequency was
detected (p < 0.05), as the thresholds elevated by ~10–15
dB at 5 and 10 kHz and to the click, but thresholds at 20
and 40 kHz did not change over the 3-month treatment
period. No main effects of treatment group were detected.
The second experiment started the gavage ALCAR treat-
ments in rats at 18 months of age (n = 9 treated, 9 con-
trols). ABR thresholds were measured at 18 months (pre-
treatment), 19, 20, 21 (final test after treatment con-
cluded), 22, and 23 months. The 22 and 23-month tests
were performed to assess whether the treatments had any
delayed effects that would manifest after the treatment
period had concluded. Figure 2 displays the thresholds at
the 18-month test (Top Panel), 21-month test (Middle
Panel), and the 23-month test (Bottom Panel). Three-fac-
tor ANOVA revealed no significant interactions involving
treatment group. A significant interaction of Time of test ×
Frequency was detected (p < 0.05), as the thresholds ele-
vated substantially over the 5-month observation period,
though the extent of the changes varied with frequency.
No main effects of treatment group were detected.
The third experiment used i.p. injections of ALCAR daily
for one month, starting at age 24 months. ABR thresholds
were measured at 24 months (pre-treatment) and 25
months (final test after treatment concluded). Figure 3
displays the thresholds at the 25-month test for the
ALCAR-treated and saline-treated groups. Three-factor
ANOVA revealed no significant interactions. A significant
main effect Frequency was detected (p < 0.05), as the
thresholds varied across stimulus frequency. No main
effects of test time or treatment group were detected, indi-
cating no changes in hearing over the one-month treat-
ment period, nor any differences between the treated and
untreated groups.
All saline-treated control groups were compared to age-
matched untreated, unhandled controls from previous
experiments. No differences were found between the
saline controls and the unhandled controls for either the
gavage or i.p. injection treatment paradigm, indicating no
effects from the handling, gavaging, or i.p. injections.
Discussion
The F344/NHsd rats showed no protective effects on their
ARHL from the daily treatments with ALCAR, nor did the
oldest animals show any reversal of their hearing loss
from the more aggressive i.p. injection treatments. ALCAR
was chosen because of the link between mitochondrial
inefficiency and age-related OHC degeneration [6,7].
Additionally, ALCAR has been shown to protect the ear
against noise-induced hearing loss [12-14], with the
mechanism hypothesized to be improvement in mito-
chondrial efficiency leading to a reduction in noise-
Data from the study of F344/NHsd rats starting at 15 months  of age Figure 1
Data from the study of F344/NHsd rats starting at 15 
months of age. Mean ABR thresholds in response to 5, 10, 
20, and 40 kHz tone burst stimuli, as well as a click stimulus 
are displayed for rats aged 15 (dark and open circle symbols) 
and 18 months (dark and open triangle symbols). 9 animals 
were treated for three months with ALCAR (dark circle and 
dark triangle symbols); 9 were treated with saline as controls 
(open circle and triangle symbols). Error bars are +/- 1 stand-
ard deviation.Journal of Negative Results in BioMedicine 2008, 7:4 http://www.jnrbm.com/content/7/1/4
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induced reactive oxygen species formation. Finally,
ALCAR was used in a small study on the F344 rat's ARHL,
and a small, but significant reduction in hearing thresh-
olds was found in 24 month-old rats treated for 6 weeks
with daily injections of 300 mg/kg ALCAR [10].
The lack of a demonstrated effect in the current studies is
difficult to interpret, beyond the interpretation that the
100 mg/kg dose of ALCAR delivered to the F344/NHsd rat
via the route (oral gavage and i.p. injection) on the dosing
schedules that were employed is not effective in protecting
against or reducing ARHL. Different doses, specifically a
higher dose (300 mg/kg) that was used by Seidman
(2000) may have been more effective. Different drugs, dif-
ferent animal models of ARHL, different dosing schedules
all may prove to be more effective than those employed in
the current studies. Specifically, starting treatment at 12
months of age may be effective, since high frequency (20
and 40 kHz) threshold appear to increase considerably
between 12 and 15 months (comparing results from
Bielefeld et al., (2008) in the 12 month-old rats to the cur-
rent data on 15 month-old rats). It remains possible that
systemic treatments did not permit enough ALCAR into
the cochlea in order to influence cell survival, nor is it
known whether the ALCAR treatments do indeed improve
mitochondrial performance or reduce oxidative stress.
Such questions will be the topics for future studies.
Data from the study of F344/NHsd rats starting at 24 months  of age Figure 3
Data from the study of F344/NHsd rats starting at 24 
months of age. Mean ABR thresholds in response to 5, 10, 
20, and 40 kHz tone burst stimuli, as well as a click stimulus 
are displayed for rats aged 25 months. 4 animals were 
treated for one month from age 24 months to age 25 months 
with ALCAR (dark circle symbols); 4 were treated with 
saline as controls (open circle symbols). Error bars are +/- 1 
standard deviation.
Data from the study of F344/NHsd rats starting at 18 months  of age Figure 2
Data from the study of F344/NHsd rats starting at 18 
months of age. Mean ABR thresholds in response to 5, 10, 
20, and 40 kHz tone burst stimuli, as well as a click stimulus 
are displayed for rats aged 18 (Top Panel), 21 months (Mid-
dle Panel), and 23 months (Bottom Panel). 9 animals were 
treated for three months with ALCAR (dark circle symbols); 
9 were treated with saline as controls (open circle symbols). 
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Conclusion
While treatment with ALCAR is thought to improve OHC
mitochondrial efficiency, thereby reducing oxidative
stress in these cells, no benefits of treatment with ALCAR
in aging F344/NHsd rats were detected. The goal of find-
ing pharmacologic strategies to prevent or reverse ARHL
remains a worthwhile topic that warrants further study.
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